ICAD Dana dhuwit perusahaan iCAD, Inc.

ICAD (icadmed.com) - tandha merek perusahaan

iCAD, Inc. (ICAD) minimizes capital expenditures by utilizing the cloud infrastructure of external providers. The SaaS model for oncology diagnostics allows the business to scale easily through clinic subscriptions. The company's free cash flow reflects current liquidity trends, with the value holding at 0.02. Revenue stability is ensured by a combination of software license sales and the supply of specialized medical equipment.

ICAD - Dhuwit awis perusahaan iCAD ing rentang 04.07.2022 - 02.08.2025

Rincian analitis lan laporan data perusahaan iCAD, Inc. (ICAD)

- kuotasi lan prakiraan analis:
Analisis fundamental perusahaan:iCAD Inc.
Produk merek iCAD Corp

This metric captures the volume of liquid assets, determining the company's ability to cover operating expenses without resorting to debt capital. By analyzing cash flow dynamics, an investor assesses the rate of spending or accumulation. The amount of cash and cash equivalents serves as a diagnostic for the business's financial autonomy. For iCAD, Inc. (ICAD), this reserve is critical when scaling SaaS subscriptions. Sufficient capital ensures the development of the ProFound AI AI platform and expansion into US oncology centers.

Analisis perusahaan pesaing

Volume dana dhuwit perusahaan ONC|HALO - Cadangan dhuwit perusahaan|Revolution Medicines - Dhuwit awis perusahaan|Volume dana dhuwit perusahaan Ascentage Pharma AAPG|CGON - Dana dhuwit perusahaan|Total volume dana dhuwit perusahaan URGN|BCAX: Volume dana dhuwit perusahaan|PSNL - Aset likuid perusahaan|ERAS (Erasca Inc) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Delcath Systems Inc DCTH|Dana dhuwit perusahaan YmAbs (YMAB)|Aset likuid perusahaan Aura Bio|Volume dana dhuwit perusahaan CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Cadangan dhuwit perusahaan|SELLAS Life Sciences Group - Volume dana dhuwit perusahaan|ACTU - Volume dana dhuwit perusahaan|CTOR: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan TuHURA (HURA)|TARA (Protara Therapeutics Inc) - Volume dana dhuwit perusahaan|Fate Therapeutics, Inc. (FATE) - Aset likuid perusahaan|Dhuwit awis perusahaan WHWK (Aadi Bioscience, Inc.)|Aset likuid perusahaan TScan Therapeutics, Inc.|Volume dana dhuwit perusahaan CSBR (Champions Oncology Corp)|Gunggung dana dhuwit perusahaan XBIT (XBiotech USA)|CVM - Dana dhuwit perusahaan|Sisa dhuwit perusahaan OSTX (ostherapies.com)|Radiopharm Theranostics Ltd (RADX) - Dana dhuwit perusahaan|ARTV: Gunggung dana dhuwit perusahaan|ANL (adlainortye.com) - Volume dana dhuwit perusahaan|VERU: Sisa dhuwit perusahaan|Dhuwit awis perusahaan TPST (Tempest Tx)|Dhuwit awis perusahaan Xilio XLO|Volume dana dhuwit perusahaan RENB (Renovaro)|Volume dana dhuwit perusahaan Mural Bio MURA|Kairos Pharma Ltd - Volume dana dhuwit perusahaan|OnKure Therapeutics (OKUR) - Dhuwit awis perusahaan|GDTC: Volume dana dhuwit perusahaan|Curis Inc. - Sisa dhuwit perusahaan|Dana dhuwit perusahaan apollomicsinc.com|THAR: Sisa dhuwit perusahaan|Dana dhuwit perusahaan Advanced Biomed Corp (ADVB)|GNPX (Genprex, Inc) - Sisa dhuwit perusahaan|Volume dana dhuwit perusahaan CLDI (Calidi Biotherapeutics)|sunshinebiopharma.com (SBFM) - Cadangan dhuwit perusahaan|Xenetic Bio - Volume dana dhuwit perusahaan|SLRX (Salarius Pharmaceuticals, Inc.) - Dhuwit awis lan setara dhuwit awis perusahaan|PPBT: Volume dana dhuwit perusahaan|Dhuwit awis perusahaan American Oncology Network Inc|BGNE (beigene.com) - Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan CKPT (Checkpoint Therapeutics)|Dhuwit awis perusahaan ELEV (Elevation Oncology Inc.)|Dhuwit awis perusahaan Ikena IKNA|Volume dana dhuwit perusahaan NTBL (notablelabs.com)|VIRX - Dhuwit awis perusahaan|MOR: Dhuwit awis perusahaan|NAYA - Volume dana dhuwit perusahaan|Ascentage Pharma (AAPGV) - Dana dhuwit perusahaan